J Korean Pediatr Soc.  1997 Feb;40(2):167-172.

Pertussis Antibodies in the Sera of Children after Acellular Pertussis Vaccination

Affiliations
  • 1Department of Pediatrics, Catholic University Medical College, Seoul, Korea.

Abstract

PURPOSE
The pertussis vaccines are divided into whole-cell vaccine and acellular vaccine. Purified component acellular pertussis vaccine, originally developed in Japan, has been used for primary immunization series in Korea since 1984. We performed this study to evaluate the prevalence of pertussis antibodies following vaccination with acellular pertussis vaccine.
METHODS
We randomized 80 children who were immunized according to vaccine schedules including less than 2 month-old infants at Department of Pediatrics, Catholic University Medical College from February 1995 to October 1995. We measured agglutination titers of children by bacterial agglutination test.
RESULTS
1) The age distribution ranged from 5 days to 7 years old, the mean age was 14.5+/- 12.8 months and male to female ratio was 1:1. 2) Only 23 cases (28.8%) of the 80 cases were positive results. 3) Among 7 infants who were less than 2 months-old and were not immunized, 5 infants (71.4%) were seropositive. 4) There was no significant difference in positive rates among age groups which include 2 to 6 months age group, 7 to 18 months age group, and older than 18 months age group.
CONCLUSIONS
The prevalence of pertussis positive rates is only 28.8% and there was no difference among age groups.

Keyword

Acellular pertussis vaccine; Antibody titer

MeSH Terms

Age Distribution
Agglutination
Agglutination Tests
Antibodies*
Appointments and Schedules
Child*
Female
Humans
Immunization
Infant
Japan
Korea
Male
Pediatrics
Pertussis Vaccine
Prevalence
Vaccination*
Vaccines
Whooping Cough*
Antibodies
Pertussis Vaccine
Vaccines
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr